Gene · 429
Papers4,495
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,121 to 1,140 of 4,495
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Application and prospects of high-throughput screening for in vitro neurogenesis. | World J Stem Cells | 2022 | 35949394 | PubTator, text mining | PubMed |
| New Insights into the Epigenomic Landscape of Small-Cell Lung Cancer: A Game Changer? | Am J Respir Crit Care Med | 2022 | 35947642 | PubTator, text mining | PubMed |
| Prenatal Exposure to Gabapentin Alters the Development of Ventral Midbrain Dopaminergic Neurons. | Front Pharmacol | 2022 | 35942222 | PubTator, text mining | PubMed |
| The Tumor Immune Microenvironment and Frameshift Neoantigen Load Determine Response to PD-L1 Blockade in Extensive-Stage SCLC. | JTO Clin Res Rep | 2022 | 35941997 | PubTator, text mining | PubMed |
| cfDNA methylome profiling for detection and subtyping of small cell lung cancers. | Nat Cancer | 2022 | 35941262 | PubTator, text mining | PubMed |
| Interleukin-17D promotes lung cancer progression by inducing tumor-associated macrophage infiltration via the p38 MAPK signaling pathway. | Aging (Albany NY) | 2022 | 35939336 | PubTator, text mining | PubMed |
| Transcriptome Dynamics in the Developing Larynx, Trachea, and Esophagus. | Front Cell Dev Biol | 2022 | 35938172 | PubTator, text mining | PubMed |
| Identification of Genes Predicting Poor Response of Trastuzumab in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer. | J Immunol Res | 2022 | 35935587 | PubTator, text mining | PubMed |
| Combinatorial transcriptional regulation of HEB/ZEB1/ASCL1 and MYBL2 on Ras/ErbB signaling. | Biochem Biophys Res Commun | 2022 | 35932528 | PubTator, text mining | PubMed |
| ASURAT: functional annotation-driven unsupervised clustering of single-cell transcriptomes. | Bioinformatics | 2022 | 35924984 | PubTator, text mining | PubMed |
| DNA Methylation Analysis to predict Regression of high-grade anal Intraepithelial Neoplasia in HIV+ men (MARINE): a cohort study protocol. | BMJ Open | 2022 | 35922105 | PubTator, text mining | PubMed |
| Inhibition of LSD1 with Bomedemstat Sensitizes Small Cell Lung Cancer to Immune Checkpoint Blockade and T-Cell Killing. | Clin Cancer Res | 2022 | 35920742 | PubTator, text mining | PubMed |
| Therapeutic potential of inhibiting histone 3 lysine 27 demethylases: a review of the literature. | Clin Epigenetics | 2022 | 35915507 | PubTator, text mining | PubMed |
| Molecular Heterogeneity in Pediatric Malignant Rhabdoid Tumors in Patients With Multi-Organ Involvement. | Front Oncol | 2022 | 35912263 | PubTator, text mining | PubMed |
| Human Immunocompetent Model of Neuroendocrine Liver Metastases Recapitulates Patient-Specific Tumour Microenvironment. | Front Endocrinol (Lausanne) | 2022 | 35909511 | PubTator, text mining | PubMed |
| The Role of Non-Coding RNAs in the Pathogenesis of Parkinson's Disease: Recent Advancement. | Pharmaceuticals (Basel) | 2022 | 35890110 | PubTator, text mining | PubMed |
| A Drug Repurposing Screen Identifies Fludarabine Phosphate as a Potential Therapeutic Agent for N-MYC Overexpressing Neuroendocrine Prostate Cancers. | Cells | 2022 | 35883689 | PubTator, text mining | PubMed |
| Developmental Cues and Molecular Drivers in Myelinogenesis: Revisiting Early Life to Re-Evaluate the Integrity of CNS Myelin. | Curr Issues Mol Biol | 2022 | 35877446 | PubTator, text mining | PubMed |
| Chemical Replacement of Noggin with Dorsomorphin Homolog 1 for Cost-Effective Direct Neuronal Conversion. | Cell Reprogram | 2022 | 35877103 | PubTator, text mining | PubMed |
| Bioactivation and reactivity research advances - 2021 year in review. | Drug Metab Rev | 2022 | 35876116 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/429/papers?page=57